KANGHUI PHARMACEUTICAL released its performance for the first half of the year, with a net loss attributable to the parent company of 40.2036 million yuan, an increase of 362.01%
KANGHUI PHARMACEUTICAL released its semi-annual report for 2025, with operating revenue of 248 million yuan, a year-on-year decrease of 6.83%. The net loss attributable to the parent company was 40.2036 million yuan, a year-on-year increase of 362.01%. The net loss after deducting non-recurring gains and losses was 42.8271 million yuan, a year-on-year increase of 167.89%. The basic loss per share was 0.4 yuan
According to the Zhitong Finance APP, KANGHUI PHARMACEUTICAL (603139.SH) released its semi-annual report for 2025, reporting an operating income of 248 million yuan, a year-on-year decrease of 6.83%. The net loss attributable to shareholders of the listed company was 40.2036 million yuan, a year-on-year increase of 362.01%. The net loss attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 42.8271 million yuan, a year-on-year increase of 167.89%. The basic loss per share was 0.4 yuan
